210 related articles for article (PubMed ID: 33662833)
1. Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection.
Manisty C; Treibel TA; Jensen M; Semper A; Joy G; Gupta RK; Cutino-Moguel T; Andiapen M; Jones J; Taylor S; Otter A; Pade C; Gibbons J; Lee J; Bacon J; Thomas S; Moon C; Jones M; Williams D; Lambourne J; Fontana M; Altmann DM; Boyton R; Maini M; McKnight A; Chain B; Noursadeghi M; Moon JC
EBioMedicine; 2021 Mar; 65():103259. PubMed ID: 33662833
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
4. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I
J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505
[TBL] [Abstract][Full Text] [Related]
5. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies.
Fenwick C; Croxatto A; Coste AT; Pojer F; André C; Pellaton C; Farina A; Campos J; Hacker D; Lau K; Bosch BJ; Gonseth Nussle S; Bochud M; D'Acremont V; Trono D; Greub G; Pantaleo G
J Virol; 2021 Jan; 95(3):. PubMed ID: 33144321
[TBL] [Abstract][Full Text] [Related]
6. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
7. Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
Takeshita M; Nishina N; Moriyama S; Takahashi Y; Uwamino Y; Nagata M; Aoki W; Masaki K; Ishii M; Saya H; Kondo Y; Kaneko Y; Suzuki K; Fukunaga K; Takeuchi T;
Virology; 2021 Mar; 555():35-43. PubMed ID: 33450669
[TBL] [Abstract][Full Text] [Related]
8. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
9. Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
Guarino C; Larson E; Babasyan S; Rollins A; Joshi LR; Laverack M; Parrilla L; Plocharczyk E; Diel DG; Wagner B
PLoS One; 2022; 17(1):e0262868. PubMed ID: 35061843
[TBL] [Abstract][Full Text] [Related]
10. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
[TBL] [Abstract][Full Text] [Related]
11. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
[TBL] [Abstract][Full Text] [Related]
12. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
13. Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
Portilho AI; Silva VO; Ahagon CM; Matsuda EM; de Oliveira EL; da Silveira EPR; de Souza Lima AK; Lindoso JAL; de Campos IB; Hong MA; De Gaspari E; de Macedo Brígido LF
J Med Virol; 2022 Jan; 94(1):178-185. PubMed ID: 34428312
[TBL] [Abstract][Full Text] [Related]
14. Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
Szymczak A; Jędruchniewicz N; Torelli A; Kaczmarzyk-Radka A; Coluccio R; Kłak M; Konieczny A; Ferenc S; Witkiewicz W; Montomoli E; Miernikiewicz P; Bąchor R; Dąbrowska K
J Gen Virol; 2021 Nov; 102(11):. PubMed ID: 34816794
[TBL] [Abstract][Full Text] [Related]
15. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
Lumley SF; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Jeffery K; Eyre DW;
N Engl J Med; 2021 Feb; 384(6):533-540. PubMed ID: 33369366
[TBL] [Abstract][Full Text] [Related]
16. A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
Cameron A; Porterfield CA; Byron LD; Wang J; Pearson Z; Bohrhunter JL; Cardillo AB; Ryan-Muntz L; Sorensen RA; Caserta MT; Angeloni S; Hardy DJ; Zand MS; Pecora ND
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139422
[TBL] [Abstract][Full Text] [Related]
17. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study.
Masiá M; Fernández-González M; Telenti G; Agulló V; García JA; Padilla S; García-Abellán J; Galiana A; Gonzalo-Jiménez N; Gutiérrez F
J Autoimmun; 2021 Sep; 123():102703. PubMed ID: 34303083
[TBL] [Abstract][Full Text] [Related]
18. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
[TBL] [Abstract][Full Text] [Related]
19. Nucleocapsid and Spike Protein-Based Anti-SARS-CoV-2 Assay Performance in the Minority and Rural Coronavirus Insights Study: Characteristics of Socioeconomically Disadvantaged Populations with Health Disparities.
Christenson RH; Hansel S; II'yasova D; Meyer WA; Puckrein G; Lee L; Landry LG; Akinboboye O
J Appl Lab Med; 2024 May; 9(3):493-501. PubMed ID: 38384143
[TBL] [Abstract][Full Text] [Related]
20. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
